News in brief - October 2013

Other new launches, licence changes and updates relevant to general practice.

The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment  of type II diabetes.
The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment of type II diabetes.
  • Onglyza (saxagliptin) can now be prescribed as monotherapy in type II diabetes inadequately controlled by diet and exercise when metformin is contraindicated or not tolerated.
  • Adults with symptomatic anaemia associated with chronic renal failure being treated with Aranesp (darbepoetin alfa) may now receive once monthly dosing in the correction phase of treatment provided they are not undergoing dialysis.
  • Generic sildenafil tablets are now listed in MIMS for the treatment of erectile dysfunction.
Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Onglyza approved for triple oral therapy

Onglyza approved for triple oral therapy

Onglyza (saxagliptin) can now be used in combination...

Pancreatitis risk with DPP4 inhibitors

Pancreatitis risk with DPP4 inhibitors

Acute pancreatitis is now listed as a possible adverse...

Onglyza licence extended for use in combination with insulin

Onglyza licence extended for use in combination with insulin

Onglyza (saxagliptin) can now be prescribed in combination...

Onglyza approved for use in renal impairment

Onglyza approved for use in renal impairment

The licence for Onglyza (saxagliptin) has been extended...

Onglyza accepted for use in NHS Scotland
New DPP4 inhibitor launched

New DPP4 inhibitor launched

Bristol Myers-Squibb and AstraZeneca have launched...

Aranesp dose regimens simplified

Dialysis patients with chronic renal failure receiving...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more